微信公众号

官网二维码

中国癌症防治杂志 ›› 2012, Vol. 4 ›› Issue (3): 246-251.doi: 10.3969/j.issn.1674-5671.2012.03.10

• 临床研究 • 上一篇    下一篇

RASSF1A与Elf-1在非小细胞肺癌中的表达及临床意义

  

  1. 滨州医学院山东省高校肿瘤分子生物学重点实验室、生物化学与分子生物学教研室
  • 出版日期:2012-09-25 发布日期:2012-10-15
  • 通讯作者: 孔丽君 E-mail:kong_lijun@163.com
  • 基金资助:

    烟台市科学技术发展计划项目 (2008162)

Expression and clinical significance of RASSF1A and Elf-1 in non-small cell lung cancer

  • Online:2012-09-25 Published:2012-10-15

摘要: 目的 利用组织芯片技术结合免疫组化方法探讨RASSF1A和Elf-1基因在非小细胞肺癌(NSCLC)组织中的蛋白表达及与临床病理学特征的关系。方法 构建含有72例非小细胞肺癌及10例正常肺组织标本的组织芯片,以免疫组织化学PowerVision TM-900(PV-9000)法检测RASSF1A和Elf-1在NSCLC与正常肺组织中的蛋白表达。结果 RASSF1A和Elf-1在肺癌组织中均呈异质性表达。RASSF1 A在NSCLC组织中的阳性率为47.22%(34/72),显著低于正常肺组织100%(10/10),两组间的蛋白表达差异具有统计学意义(P=0.002);RASSF1A在有淋巴结转移组的表达强度显著低于无淋巴结转移组(X2=4.379,P=0.036);RASSF1A的表达在不同的临床分期间差异有统计学意义(X2 =17.979,P =0.000)。Elf-1在NSCLC及正常肺组织中的阳性表达率分别为73.61%(53/72)及20.00%(2/10),两组间的表达差异具有统计学意义(P=0.001),其表达强度与NSCLC的分化程度有关(X2=7.116,P=0.028); 有淋巴结转移组Elf-1的表达强度高于无淋巴结转移组( X2=5.304,P =0.021); Elf-1的表达在不同的临床分期间亦有差异(X2=6.791,P = 0.034)。NSCLC组织中RASSF1A和Elf-1蛋白的表达强度呈负相关(r =-0.433,P = 0.000)。结论 在NSCLC组织中RASSF1A表达下调和Elf-1过度表达可能与NSCLC的发生、发展及预后不良有关,RASSF1A及 Elf-1基因表达的检测有望作为NSCLC早期诊断、评估其侵袭性及转移性的重要参考指标。

关键词: 肺肿瘤, RASSF1A, Elf-1, 非小细胞肺癌, 蛋白质阵列分析, 免疫组化

Abstract: Objective To explore the correlation between the expression of RASSF1A and Elf-1 proteins and clinicopathological fea-tures of non-small cell lung cancer(NSCLC). Methods A tissue chip array containing 72 NSCLC tissue samples and 10 normal lung tissue samples was constructed,and immunohistochemistry(PV9000)was used to measure the expression of RASSF1A and Elf-1 pro-teins. Results Both RASSF1A and Elf-1 were heterogeneously expressed in NSCLC tissue. RASSF1A protein was expressed in 34/72 (47.22%) of NSCLC tissues,a significantly lower proportion than the 10/10(100%) of normal lung tissues expressing RASSF1A.In addition,RASSF1A protein levels differed significantly between NSCLC tissue and normal lung tissue(P=0.002).For example, RASSF1A protein levels were significantly higher in cases with lymph node metastasis than in cases without it(X2=4.379,P=0.036). Significant differences were also observed between groups at different clinical stages(X2=17.979,P=0.000).Elf-1 protein was detected in 53/72(73.61%) of NSCLC tissues but in only 2/10(20%) of normal lung tissues.Elf-1 protein levels differed significantly between the two types of tissue(P=0.001).Expression of Elf-1 was related to tumor differentiation(X2=7.116,P=0.028),lymph node metastasis (X2=5.304, P=0.021) and clinical staging(X2=6.791, P=0.034).Levels of RASSF1A and Elf-1 proteins correlated negatively with each other in NSCLC tissue(r =-0.433,P =0.000). Conclusions The down-regulation of RASSF1A and up regulation of Elf-1 may be asso-ciated with the occurrence,progression and prognosis of NSCLC.The relative expression of RASSF1A and Elf-1 may play an impor-tant role in early diagnosis of NSCLC,and serve as a molecular indicator for predicting invasion and metastasis.